Pharmacokinetics of oral tramadol in patients with liver cancer

Journal of Opioid Management

Volumn 4, Issue 2, 2008, Pages 99-104

  Mohamed Kotb, Hassan Ibraheem ^a   Fouad, Ihab Ahmed ^b   Fares, Khaled Mohamed ^a   Mostafa, Mostafa Galal ^a   Abd El Rahman, Ahmad M ^a  

^a ASSIUT UNIVERSITY   (Egypt)

^b University of Assiut   (Egypt)

Author keywords

Analgesics; Carcinoma; Liver; Opioid; Pharmacokinetics; Tramadol

Indexed keywords

TRAMADOL;

ADULT; ARTICLE; CANCER PAIN; CANCER PATIENT; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DROWSINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; HEPATITIS C; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER CANCER; LIVER CARCINOMA; LIVER METASTASIS; MAXIMUM PLASMA CONCENTRATION; NAUSEA; SIDE EFFECT; SWEATING; TIME TO MAXIMUM PLASMA CONCENTRATION; VENOUS BLOOD;

EID: 45449093482     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2008.0014     Document Type: Article

References (23)

1. World Health Organization: Cancer Pain Relief. Geneva: World Health Organization, 1996.
2. Rodrigues N, Rodrigues PE: Tramadol in cancer pain. Curr Ther Res. 1989; 46: 1142-1148.
3. Osipova NA, Novikow GA, Beresnew VA, et al.: Analgesic effect of tramadol in cancer patients with chronic pain: A comparison with prolonged action morphine sulphate. Curr Ther Res. 1991; 50: 812-821.
4. Wilder-Smith Ch, Schinke J, Osterwalder B, et al.: Oral tramadol, a μ-opioid agonist and monoamine reuptake-blocker, and morphine for strong cancer-related pain. Ann Oncol. 1994; 5: 141-146.
5. Tawfik MO, Elbovolossy K, Wasr F: Tramadol hydrochloride in the relief of cancer pain: A double blind comparison against sustained release morphine. Pain. 1990; 41(5): S377.
6. Brema F, Pastorino G, Martini MC, et al.: Oral tramadol and buprenorphine in tumour pain: An Italian multicentre trial. Int J Clin Pharmacol Res. 1996; 16: 109-116.
7. Enggaard TP, Poulsen L, Arendt-Nielsen L, et al.: The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. Anesth Analg. 2006; 102: 146-150.
8. Muir C, Waterhouse J, Mack T, et al.: Cancer Incidence in Five Continents, World Health Organization, vol V. Lyon: IARC, 1987. No. 88.
9. Rustgi VK: Epidemiology of hepatocellular carcinoma. Gastroenterol Clin North Am. 1987; 16: 545-551.
10. Kubicka S, Rudolph KL, Hanke M, et al.: Hepatocellular carcinoma in Germany: A retrospective epidemiological study from a low-endemic area. Liver 2000; 20: 312-318.
11. McLean AJ, Morgan DJ: Clinical pharmacokinetics in patients with liver disease. Clin Pharmacokinet. 1991; 21: 42-69.
12. Gibaldi M, Perrier D: Pharmacokinetics, 2nd ed. New York: Marcel Dekker, 1982; 33-42, 410-416.
13. Zwaveling J, Bubbers S, van Meurs AHJ, et al.: Pharmacokinetics of rectal tramadol in postoperative pediatric patients. Br J Anesth. 2004; 93(2): 224-227.
14. Wagner JG: Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexpomential equations which have fitted to the data. J Pharmacokinet Biopharm. 1976; 4: 443-467.
15. Yamaoka K, Nakagawa T: A non linear least square program based on differential equations. Multi (Runge) for microcomputer: J Pharmacobio Dynam. 1983; 6: 395-360.
16. Kotb HIM, El-Kady SA, Emara SES, et al.: Pharmacokinetics of controlled release morphine (MST) in patients with liver carcinoma. Br J Anesth. 2005; 94: 95-99.
17. Lintz W, Barth H, Osterloh G, et al.: Bioavailability of enteral tramadol formulations. 1st communication: Capsules. Arzneimittelforschung. 1986; 36(8): 1278-1283.
18. Bodalia B, McDonald CJ, Smith KJ, et al.: A comparison of the pharmacokinetics, clinical efficacy, and tolerability of once daily tramadol tablets with normal release tramadol capsules. J Pain Symptom Manage. 2003; 25(2): 142-149.
19. Lintz W: Overall Summary on Pharmacokinetics of Tramadol in Man. Aachen: Grünenthal GmbH, 1992.
20. Morgan DJ, McLean AJ: Clinical pharmacokinetics in patients with liver disease. Clin Pharmacokinet. 1995; 29: 370-391.
21. Sherlock S, Dooley J, eds: Diseases of the Liver and Biliary System. Oxford: Blackwell Scientific Publications, 2002. 537-561.
22. Villeneuve JP, Pichette V: Cytochrome P450 and liver diseases. Current Drug Metabolism. 2004; 5: 273-282.
23. Liu LL, Gong LK, Qi X, et al.: Altered expression of cytochrome P450 and possible correlation with pre neoplastic changes in early stage of rat hepatocorcinogenesis. Acta Pharmacologica Sinica. 2005; 26(6): 737-744.